Fig. 7

Models of BEZ235 effects in NSCLC. a A schematic representation showing that NVP-BEZ235 inhibits both PI3K and mTOR signaling induced by RTK, resulting in cell-cycle arrest at G1 phase through transcriptional and proteosome-mediated downregulation of cyclin D. b A schematic representation showing that the combination of NVP-BEZ235 and the DNA-damaging chemotherapeutic agent cisplatin is an effective antitumor strategy for NSCLC patients, and that the combination of NVP-BEZ235 with the EGFR-targeted therapeutic BIBW2992 is effective against NSCLC tumors with acquired resistance to TKIs caused by expression of the EGFR-T790 M mutant